GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (NAS:SNOA) » Definitions » Cyclically Adjusted Revenue per Share

SNOA (Sonoma Pharmaceuticals) Cyclically Adjusted Revenue per Share : $418.94 (As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sonoma Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sonoma Pharmaceuticals's adjusted revenue per share for the three months ended in Dec. 2024 was $2.434. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $418.94 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Sonoma Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -29.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -25.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -20.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -12.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sonoma Pharmaceuticals was -3.00% per year. The lowest was -25.50% per year. And the median was -9.35% per year.

As of today (2025-05-14), Sonoma Pharmaceuticals's current stock price is $3.07. Sonoma Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was $418.94. Sonoma Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 0.01.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sonoma Pharmaceuticals was 0.70. The lowest was 0.01. And the median was 0.09.


Sonoma Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Sonoma Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Sonoma Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,572.44 1,338.70 1,081.04 768.81 553.40

Sonoma Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 590.35 553.40 507.38 461.50 418.94

Competitive Comparison of Sonoma Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


;
;

Sonoma Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sonoma Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=2.434/133.1571*133.1571
=2.434

Current CPI (Dec. 2024) = 133.1571.

Sonoma Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 265.333 99.621 354.654
201506 216.471 100.684 286.289
201509 225.222 100.392 298.730
201512 137.944 99.792 184.064
201603 128.750 100.470 170.637
201606 114.696 101.688 150.191
201609 121.652 101.861 159.029
201612 146.130 101.863 191.024
201703 167.875 102.862 217.317
201706 159.792 103.349 205.879
201709 180.208 104.136 230.430
201712 201.792 104.011 258.338
201803 130.536 105.290 165.086
201806 124.829 106.317 156.343
201809 137.194 106.507 171.523
201812 107.755 105.998 135.364
201903 66.394 107.251 82.432
201906 67.090 108.070 82.664
201909 71.621 108.329 88.036
201912 58.600 108.420 71.970
202003 48.449 108.902 59.240
202006 62.685 108.767 76.741
202009 53.417 109.815 64.771
202012 47.922 109.897 58.065
202103 20.740 111.754 24.712
202106 35.086 114.631 40.756
202109 32.000 115.734 36.817
202112 18.844 117.630 21.331
202203 14.826 121.301 16.275
202206 25.697 125.017 27.370
202209 21.490 125.227 22.851
202212 18.994 125.222 20.198
202303 14.150 127.348 14.795
202306 13.874 128.729 14.351
202309 10.585 129.860 10.854
202312 5.747 129.419 5.913
202403 4.409 131.776 4.455
202406 3.985 132.554 4.003
202409 3.461 133.029 3.464
202412 2.434 133.157 2.434

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Sonoma Pharmaceuticals  (NAS:SNOA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sonoma Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.07/418.94
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sonoma Pharmaceuticals was 0.70. The lowest was 0.01. And the median was 0.09.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sonoma Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Executives
Chad Norman White officer: Interim CFO 645 MOLLY LANE, SUITE 150, WOODSTOCK GA 30189
Jerome J Dvonch officer: Chief Financial Officer 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Robert Grant Edwards officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Poggetto John Dal officer: Chief Financial Officer 1129 N. MCDOWELL BLVD, PETALUMA CA 94954
Amy Moss Trombly officer: Interim CEO 1314 MAIN STREET, SUITE 102, LOUSIVILLE CO 80027
Frederick J Sandford director, officer: CEO and Interim CFO C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Philippe Weigerstorfer director 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert E Miller officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
James J Schutz director, officer: Chief Operating Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Marc Umscheid officer: Chief Strategy/Mkt Officer OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert Allen Northey officer: Exec. VP of Res & Devlpment C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Russell Joseph Harrison director OCULUS INNOVATIVE SCIENCES, INC., 1129 NORTH MCDOWELL BLVD., PETALUMA CA 94954
John Mclaughlin director OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sameer Harish other: Officer of Subsidiary (1) RUTHIGEN, INC., 1129 N. MCDOWELL BLVD, PETALUMA CA 94954